

DAFTAR PUSTAKA

1. Sukrisman L, Kurnianda J. Leukemia mieloblastik akut. . In: Alwi I, Setiati S, Syam AF, Sudoyo AW, Kolopaking MS, Nasution SA, editors. Buku Ajar Ilmu Penyakit Dalam. VII. Jakarta: Interna Publishing; 2024. p. 3224–32.
2. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. *Int J Cancer*. 2021.
3. Zhou Y, Huang G, Cai X, Liu Y, Qian B, Li D. Global, regional, and national burden of acute myeloid leukemia, 1990–2021: a systematic analysis for the global burden of disease study 2021. *Biomark Res*. 2024;12:101.
4. Harystha M. Gambaran karakteristik pasien leukemia mieloid akut di bagian penyakit dalam RSUP DR. M. Djamil Padang periode Juli 2015 - Juni 2016. eSkripsi Universitas Andalas. 2016.
5. Jimbu L, Valeanu M, Adrian T, Mesaros O, Bojan A, Dima D, et al. A Survival Analysis of Acute Myeloid Leukemia Patients Treated With Intensive Chemotherapy: A Single Center Experience. *Cureus*. 2023.
6. Albuquerque KMC de, Joventino CB, Moreira LC, Rocha HAL, Gurgel LA, Oliveira D de S, et al. Clinical outcome and prognosis of patients with acute myeloid leukemia submitted to chemotherapy with 5 years of follow-up. *Hematol Transfus Cell Ther*. 2024;46:8–13.
7. Franco S, Geng X, Korostyshevskiy V, Karp JE, Lai C. Systematic review and meta-analysis: Prognostic impact of time from diagnosis to treatment in patients with acute myeloid leukemia. *Cancer*. 2023;129:2975–85.
8. Liu CJ, Hong YC, Kuan AS, Yeh CM, Tsai CK, Liu YC, et al. The risk of early mortality in elderly patients with newly diagnosed acute myeloid leukemia. *Cancer Med*. 2020;9:1572–80.
9. Alsulami HA, Alnashri MM, Bawazir AF, Alrashid LT, Dly RA, Alharbi YA, et al. Prognostics and clinical outcomes in patients diagnosed with acute myeloid leukemia (AML) in a teaching hospital. *Cureus*. 2021.
10. Mendoza-Urbano DM, Tello-Cajiao ME, Rosales J, Ahumada FE, Parra-Lara LG, Arrieta E. Survival in Elderly Patients Diagnosed With Acute Myeloid Leukemia: A Hospital-Based Study. *J Hematol*. 2023;12:7–15.
11. Venditti A, Cairoli R, Caira M, Finsinger P, Finocchiaro F, Neri B, et al. Assessing eligibility for treatment in acute myeloid leukemia in 2023. *Expert Rev Hematol*. 2023;16:181–90.
12. Negotei C, Mitu I, Angelescu S, Gradinaru F, Mambet C, Stanca O, et al. Incorporation of a comorbidity index in treatment decisions for elderly AML patients can lead to better disease management-a single-center experience. *Hematol Rep*. 2024;16:781–94.
13. Javaid S, Frasier K, Vinagolu-Baur J, Li V. Elucidating the Role of Malnutrition in Acute Leukemia Patients and How it Leads to Adverse Events During Hospitalization: An Interesting Study Journal on Oncology [Internet]. 2024 Jan. Available from: www.journalononcology.org
14. Van de Louw A, Zhu X, Frankenfield D. Obesity and malnutrition in critically ill patients with acute myeloid leukemia: Prevalence and impact on mortality. *Nutrition*. 2020;79–80:110956.

15. Çınar OE, Malkan ÜY, Aladağ E, Demiroğlu H, Büyükaşık Y, Göker H, et al. Anemia in the patients with acute myeloid leukemia revisited: Prognostic importance of anemia on treatment-naïve patients. *Acta Med.* 2025;56:116–21.
16. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. *Blood.* 2022;140:1345–77.
17. Ally F, Chen X. Acute Myeloid Leukemia: Diagnosis and Evaluation by Flow Cytometry. *Cancers (Basel).* 2024;16:3855.
18. Elakkad M, Abdelhalim A, Salah H, Amer A. CD34 expression and FLT3 mutation are independent poor prognostic factors in normal karyotype acute myeloid leukemia. *The Egyptian Journal of Haematology.* 2019;44:48.
19. Totiger TM, Ghoshal A, Zabroski J, Sondhi A, Bucha S, Jahn J, et al. Targeted therapy development in acute myeloid leukemia. *Biomedicines.* 2023;11:641.
20. Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, et al. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. *Am J Hematol.* 2022;97:68–78.
21. Pelcovits A, Niroula R. Acute Myeloid Leukemia: A Review [Internet]. 2020. Available from: <https://seer.cancer.gov/statfacts/>
22. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. *Blood Cancer J.* 2016;6:e441–e441.
23. Dia Rofinda Z. Kelainan hemostasis pada leukemia. *Jurnal Kesehatan Andalas.* 2012;1.
24. Vakiti A, Reynolds SB, Mewawalla P. Acute Myeloid Leukemia. 2025.
25. Basturk A, Akinci S, Hacibekiroglu T, Guney T, Kutlucan A, Ceran F, et al. Prognostic significance of flow cytometry findings in Turkish adult acute leukemia patients. *Eur Rev Med Pharmacol Sci.* 2015;19:3360–6.
26. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. *Blood.* 2022;140:1345–77.
27. Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. *Am J Hematol.* 2023;98:502–26.
28. Pollyea DA, Altman JK, Chair V, Assi R, Bachiasvili K, Raj Bhatt V, et al. NCCN Guidelines Version 2.2025 Acute Myeloid Leukemia (Age ≥ 18 years) [Internet]. 2025. Available from: <https://www.nccn.org/home/member->
29. Dhopeshwarkar N, Iqbal S, Wang X, Salas M. A retrospective study of comorbidities and complications in elderly acute myeloid leukemia patients in the united states. *Clin Lymphoma Myeloma Leuk.* 2019;19:e436–56.
30. Pawelec G. Age and immunity: What is “immunosenescence”? *Exp Gerontol.* 2018;105:4–9.
31. Storey S, Gray TF, Bryant AL. Comorbidity, Physical Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia. *Curr Geriatr Rep.* 2017;6:247–54.
32. Kantarjian H, Ravandi F, O'Brien S, Cortes J, Faderl S, Garcia-Manero G, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. *Blood.* 2010;116:4422–9.
33. Klepin HD. Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly. *Clin Geriatr Med.* 2016;32:155–73.

34. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. *Blood*. 2006;107:3481–5.
35. Etienne A, Esterni B, Charbonnier A, Mozziconacci M, Arnoulet C, Coso D, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. *Cancer*. 2007;109:1376–83.
36. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. *Blood*. 2005;106:2912–9.
37. Janscak M, Stelmes A, van den Berg J, Heim D, Halter J, Drexler B, et al. Influence of comorbidities on outcome in 1102 patients with an allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2024;59:1525–33.
38. Bewersdorf JP, Zeidan AM. Hyperleukocytosis and leukostasis in acute myeloid leukemia: can a better understanding of the underlying molecular pathophysiology lead to novel treatments? *Cells*. 2020;9:2310.
39. ten Cate H, Leader A. Management of disseminated intravascular coagulation in acute leukemias. *Hamostaseologie*. 2021;41:120–6.
40. Li S, Chen L, Jin W, Ma X, Ma Y, Dong F, et al. Influence of body mass index on incidence and prognosis of acute myeloid leukemia and acute promyelocytic leukemia: A meta-analysis. *Sci Rep*. 2017;7:17998.
41. Ando T, Yamazaki E, Ogusa E, Ishii Y, Yamamoto W, Motohashi K, et al. Body mass index is a prognostic factor in adult patients with acute myeloid leukemia. *Int J Hematol*. 2017;105:623–30.
42. Pati S, Irfan W, Jameel A, Ahmed S, Shahid RK. Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management. *Cancers (Basel)*. 2023;15:485.
43. Tsilingiris D, Vallianou NG, Spyrou N, Kounatidis D, Christodoulatos GS, Karampela I, et al. Obesity and leukemia: biological mechanisms, perspectives, and challenges. *Curr Obes Rep*. 2023;13:1–34.
44. Ryan AM, Power DG, Daly L, Cushen SJ, Ní Bhuachalla É, Prado CM. Cancer-associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. *Proceedings of the Nutrition Society*. 2016;75:199–211.
45. Yeung CCS, Radich J. Predicting chemotherapy resistance in AML. *Curr Hematol Malig Rep*. 2017;12:530–6.
46. Kosasih AS, Muthalib A, Kresno SB, Setiabudy R. Profil Imunofenotip, Mutasi Gen FLT3-ITD, NPM1, dan CEBPA pada Leukemia Mieloid Akut, Serta Hubungannya dengan Luaran Klinis. [Jakarta]: Universitas Indonesia; 2015.
47. Gajendra S, Gupta R, Thakral D, Gupta SK, Jain G, Bakhshi S, et al. CD34 negative HLA-DR negative acute myeloid leukaemia: A higher association with NPM1 and FLT3-ITD mutations. *Int J Lab Hematol*. 2023;45:221–8.
48. Short NJ, Kantarjian H. When less is more: reevaluating the role of intensive chemotherapy for older adults with acute myeloid leukemia in the modern era. *Journal of Clinical Oncology*. 2021;39:3104–8.
49. Elakkad M, Abdelhalim A, Salah H, Amer A. CD34 expression and FLT3 mutation are independent poor prognostic factors in normal karyotype acute myeloid leukemia. *The Egyptian Journal of Haematology*. 2019;44:48.

50. World Health Organization Western Pacific Region. The Asia-Pacific perspective : redefining obesity and its treatment. 2002.
51. Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, et al. Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. 2020;31:697–712.
52. WHO. Guideline on haemoglobin cutoffs to define anaemia in individuals and populations. World Health Organization; 2024. 57 p.
53. Chaurasiya PS, Lamsal DK, Khatri A, Parajuli A, Shrestha PR, Aryal L, et al. Prevalence of acute myeloid leukemia and its associated risk factors at a tertiary care center: a retrospective cross-sectional study. *Annals of Medicine & Surgery*. 2023;85:4794–8.
54. Irawan C, Steven R, Gunarsa RG, Tenggara JB. Luaran Hasil Leukemia Mieloid Akut yang Menjalani Terapi pada Ruang Kemoterapi Semi-Isolasi. *Jurnal Penyakit Dalam Indonesia*. 2022;9:155.
55. Cahya Wibawa IMB, Subawa AAN, Sutirta Yasa IWP, Mahartini NN. Gambaran Karakteristik Pasien Acute Myeloid Leukemia di RSUP Sanglah Denpasar tahun 2018. *E-Jurnal Medika Udayana*. 2021;10:38.
56. Baden D, Wolgast N, Altröck PM, Steinhäuser S, Voran J, Beder T, et al. Epidemiology, survival, and treatment of acute myeloid and lymphoblastic leukaemia in Germany: a nationwide population-based registry analysis. *The Lancet Regional Health - Europe*. 2025;59:101503.
57. Philip C, George B, Ganapule A, Korula A, Jain P, Alex AA, et al. Acute myeloid leukaemia: challenges and real world data from India. *Br J Haematol*. 2015;170:110–7.
58. El Chaer F, Bewersdorf JP, Stahl M, Zeidan AM. The global epidemiology of acute myeloid leukaemia. *Nat Rev Clin Oncol*. 2026;23:107–20.
59. Shallis RM, Weiss JJ, Deziel NC, Gore SD. Challenging the concept of de novo acute myeloid leukemia: Environmental and occupational leukemogens hiding in our midst. *Blood Rev*. 2021;47:100760.
60. Han HJ, Choi K, Suh HS. Impact of aging on acute myeloid leukemia epidemiology and survival outcomes: A real-world, population-based longitudinal cohort study. *PLoS One*. 2024;19:e0300637.
61. Ozga M, Nicolet D, Mrózek K, Yilmaz AS, Kohlschmidt J, Larkin KT, et al. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG). *Leukemia*. 2024;38:45–57.
62. Tettero JM, Cloos J, Bullinger L. Acute myeloid leukemia: does sex matter? *Leukemia*. 2024;38:2329–31.
63. Muhammid HS, Hassan AJ, Abdulla HN. Evaluation the role of CD34 in patients with acute myeloid leukemia. *Int J Health Sci (Qassim)*. 2022;11677–91.
64. Arellano M, Bernal-Mizrachi L, Pan L, Tighiouart M, Souza L, Guo X, et al. Prognostic Significance of Leukopenia at the Time of Diagnosis in Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk*. 2011;11:427–32.
65. Wang Y, Wang H, Wang W, Liu W, Liu N, Liu S, et al. Prognostic value of platelet recovery degree before and after achieving minimal residual disease negative complete remission in acute myeloid leukemia patients. *BMC Cancer*. 2020;20:732.

66. Dharmani C, Wang E, Tu N, Fofah O, Cueto J, Salas M, et al. Elderly patients with acute myeloid leukemia who only receive supportive care in the Surveillance, Epidemiology and End Results-Medicare database: demographics, treatment patterns and outcomes. *Future Oncology*. 2023;19:1677–93.
67. Hubscher E, Sikirica S, Bell T, Brown A, Welch V, Russell-Smith A, et al. Patterns of undertreatment among patients with acute myeloid leukemia (AML): considerations for patients eligible for non-intensive chemotherapy (NIC). *J Cancer Res Clin Oncol*. 2021;147:3359–68.
68. Stabellini N, Tomlinson B, Cullen J, Shanahan J, Waite K, Montero AJ, et al. Sex differences in adults with acute myeloid leukemia and the impact of sex on overall survival. *Cancer Med*. 2023;12:6711–21.
69. Wiernik PH, Sun Z, Cripe LD, Rowe JM, Fernandez HF, Luger SM, et al. Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. *Br J Haematol*. 2021;194:309–18.
70. Medeiros BC, Othus M, Estey EH, Fang M, Appelbaum FR. Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. *Haematologica*. 2012;97:1401–4.
71. Percival ME, Zhang M, Othus M, McMillen K, Erba H, Garcia-Manero G, et al. Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203. 2024.
72. Zhang Y, Gu H, Chen Q, Zhang Y, Cheng H, Yang J, et al. Low Platelet Counts at Diagnosis Predict Better Survival for Patients with Intermediate-Risk Acute Myeloid Leukemia. *Acta Haematol*. 2020;143:9–18.
73. DiNardo CD, Garcia-Manero G, Pierce S, Nazha A, Bueso-Ramos C, Jabbour E, et al. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia and myelodysplastic syndrome. *Am J Hematol*. 2016;91:227–32.
74. Amer A, Abdelhaleim ayman, Salah hossam E. CD34 Expression in Adult Acute Myeloid Leukemia is an Independent Poor Prognostic Factor. *Zagazig University Medical Journal*. 2019;0:0–0.
75. Raspadori D, Lauria F, Ventura MA, Rondelli D, Visani G, de Vivo A, et al. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: Analysis of 141 cases. *Leuk Res*. 1997;21:603–7.
76. Chung J, Shin HJ, Choi YJ, Cho GJ, Joo YD, Lee WS, et al. Prognostic value of CD34 expression in patients with acute myeloid leukemia treated by conventional chemotherapy. *Blood*. 2005;106:4561.
77. Liu H, Stanworth SJ, McPhail S, Bishton M, Rous B, Bacon A, et al. Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013-2020. *Blood Adv*. 2024;8:4593–605.
78. Medeiros BC, Satram-Hoang S, Hurst D, Hoang KQ, Momin F, Reyes C. Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. *Ann Hematol*. 2015;94:1127–38.
79. Legrand O, Perrot JY, Baudard M, Cordier A, Lautier R, Simonin G, et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. *Blood*. 2000;96:870–7.